Author of

• 18975

  +

  P3.01 - Advanced NSCLC (ID 621)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23938

    +

    P3.01-079 - Evaluating the Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Stage IIIa (N2) Lung Cancer (ID 10124)

    09:30 - 09:30  |  Presenting Author(s): Luo-Sheng Yong
    • Abstract

    Background:
    The survival benefit of systemic chemotherapy has been demonstrated for treating patients with stage IIIa (N2+) lung cancer. The NCCN guideline recommends induction chemotherapy with or without irradiation followed by surgery for those patients if no disease progression was noted after induction therapy. However, there are also studies revealed the survival benefit of adjuvant chemotherapy for patients with N2+ IIIa disease. The current study compared the survival results of neoadjuvant (before surgery, BS) and adjuvant (after surgery, AS) chemotherapy plus surgical resection for the patients with non-small cell lung cancer with N2+ stage IIIa disease.
    
    Method:
    There were 217 patients with Stage IIIa N2+ who ercieved surgery resection in the recent decade in our hospital, with a mean follow-up duration of 44 months. The overall survival time was evaluated and compared between these three groups of patients
    
    Result:
    Figure 1There were 62, 44 and 111 patients without chemotherapy(C/T) (Nil) or C/T given as neoadjuvant (BS) and adjuvant (AS) setting respectively. There were more patients with advanced age in the Nil and AS groups and more patients with AS group have received sublobal resection (p<0.01 respectively) as compared to the patients of BS group. The mean survival duration after surgery for the patients of AS and BS groups was 57.6 and 50.4 months respectively which was signinficantly longer than those patients of Nil group (MST: 26.4 months : p<0.001 respectively). Multivariate analysis revealed the addition of chemotherapy as a single prognostic factor of the patients. However, there was no significant difference of survival duration between the patients of AS and BS groups.
    
    
    
    Conclusion:
    Chemotherapy given both as adjuvant or neoadjuvant setting can provide a survival benefit for the patients with stage IIIa N2+ non-small cell lung cancer after surgery. No statistical difference was observed about the survival duration for these two groups of patients.